BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Späth PJ, Granata G, La Marra F, Kuijpers TW, Quinti I. On the dark side of therapies with immunoglobulin concentrates: the adverse events. Front Immunol 2015;6:11. [PMID: 25699039 DOI: 10.3389/fimmu.2015.00011] [Cited by in Crossref: 48] [Cited by in F6Publishing: 51] [Article Influence: 6.0] [Reference Citation Analysis]
Number Citing Articles
1 Sim B, Ng JY, Teh BW, Talaulikar D. Immunoglobulin replacement in hematological malignancies: a focus on evidence, alternatives, dosing strategy, and cessation rule. Leukemia & Lymphoma 2022. [DOI: 10.1080/10428194.2022.2131424] [Reference Citation Analysis]
2 Wang Y, Khalenkov A, Scott DE. An optimized microplate-based method to evaluate complement-dependent hemolysis mediated by intravenous immunoglobulins (IVIG). Biologicals 2022:S1045-1056(22)00044-6. [PMID: 35842374 DOI: 10.1016/j.biologicals.2022.06.005] [Reference Citation Analysis]
3 Yang L, Shou YH, Li F, Zhu XH, Yang YS, Xu JH. Intravenous Immunoglobulin Combined With Corticosteroids for the Treatment of Stevens-Johnson Syndrome/Toxic Epidermal Necrolysis: A Propensity-Matched Retrospective Study in China. Front Pharmacol 2021;12:750173. [PMID: 35115922 DOI: 10.3389/fphar.2021.750173] [Reference Citation Analysis]
4 Takatsuki M, Araki T, Kanno A, Yasumoto A, Morishita E, Shiota H. Thrombosis with Thrombocytopenia Syndrome after ChAdOx1 nCoV-19 vaccination. Rinsho Shinkeigaku. [DOI: 10.5692/clinicalneurol.cn-001741] [Reference Citation Analysis]
5 Bruggeman CW, Nagelkerke SQ, Lau W, Manlhiot C, de Haas M, van Bruggen R, McCrindle BW, Yeung RSM, Kuijpers TW. Treatment-associated hemolysis in Kawasaki disease: association with blood-group antibody titers in IVIG products. Blood Adv 2020;4:3416-26. [PMID: 32722782 DOI: 10.1182/bloodadvances.2020002253] [Cited by in Crossref: 7] [Cited by in F6Publishing: 9] [Article Influence: 3.5] [Reference Citation Analysis]
6 Korsak J, Piotrowska A. Post-Transfusion Haemolytic Reactions. Human Blood Group Systems and Haemoglobinopathies 2021. [DOI: 10.5772/intechopen.91019] [Reference Citation Analysis]
7 Kalmarzi RN, Eslamian MH, Abolhassani H, Aghamohammadi A, Hammarström L, Gennery AR. Management of inborn errors of immunity. Inborn Errors of Immunity 2021. [DOI: 10.1016/b978-0-12-821028-4.00003-8] [Reference Citation Analysis]
8 Zadeh Mehrizi T, Mousavi Hosseini K. An overview on the investigation of nanomaterials' effect on plasma components: immunoglobulins and coagulation factor VIII, 2010–2020 review. Nanoscale Adv 2021;3:3730-45. [DOI: 10.1039/d1na00119a] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
9 Stoevesandt J, Heitmann J, Goebeler M, Benoit S. Neutropenie als Nebenwirkung der Therapie mit hochdosierten intravenösen Immunglobulinen in der Dermatologie. J Dtsch Dermatol Ges 2020;18:1394-404. [PMID: 33373142 DOI: 10.1111/ddg.14310_g] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
10 Stoevesandt J, Heitmann J, Goebeler M, Benoit S. Neutropenia resulting from high-dose intravenous immunoglobulin in dermatological patients. J Dtsch Dermatol Ges 2020;18:1394-403. [PMID: 33373152 DOI: 10.1111/ddg.14310] [Reference Citation Analysis]
11 Borilova Linhartova P, Gachova D, Lipovy B. Responsiveness to i.v. immunoglobulin therapy in patients with toxic epidermal necrolysis: A novel pharmaco-immunogenetic concept. J Dermatol 2020;47:1236-48. [PMID: 32935409 DOI: 10.1111/1346-8138.15583] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
12 Tagawa T, Sakuraba S. Acute massive pulmonary embolism treated by urgent pulmonary embolectomy: A case report. Clin Case Rep 2020;8:1502-1505. [DOI: 10.1002/ccr3.2913] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
13 Arcani R, Grapperon AM, Venton G, Suchon P, Verschueren A, Bas J, Salort-Campana E, Attarian S, Delmont E. Should we prevent thrombosis related to intravenous immunoglobulin infusions with systematic anticoagulant prophylaxis? Rev Neurol (Paris) 2021;177:100-6. [PMID: 32718469 DOI: 10.1016/j.neurol.2020.04.029] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
14 Bates BN, Olah ME. A New Intravenous Immune Globulin: Novel or Not? Ann Pharmacother 2021;55:117-22. [PMID: 32567360 DOI: 10.1177/1060028020934722] [Reference Citation Analysis]
15 Yang L, Shou Y, Li F, Zhu X, Yang Y, Xu J. Retrospective study of 213 cases of Stevens–Johnson syndrome and toxic epidermal necrolysis from China. Burns 2020;46:959-69. [DOI: 10.1016/j.burns.2019.10.008] [Cited by in Crossref: 18] [Cited by in F6Publishing: 18] [Article Influence: 6.0] [Reference Citation Analysis]
16 Victor JR. Do different IgG repertoires play a role in B- and T-cell functional modulation during ontogeny? The "hooks without bait" theory. Immunol Cell Biol 2020;98:540-8. [PMID: 32342552 DOI: 10.1111/imcb.12335] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 2.3] [Reference Citation Analysis]
17 Fitzpatrick EA, Wang J, Strome SE. Engineering of Fc Multimers as a Protein Therapy for Autoimmune Disease. Front Immunol 2020;11:496. [PMID: 32269572 DOI: 10.3389/fimmu.2020.00496] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 3.7] [Reference Citation Analysis]
18 Bürzle M, Hubsch A, Spiegl N, Roten T, Marques A, Martig L, Shebl A, Stadler D. Measurement of isoagglutinins in immunoglobulins for intravenous application by flow cytometry. Anal Biochem 2020;591:113534. [PMID: 31821802 DOI: 10.1016/j.ab.2019.113534] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
19 Shekunov J, Blacker CJ, Vande Voort JL, Tillema JM, Croarkin PE, Romanowicz M. Immune mediated pediatric encephalitis - need for comprehensive evaluation and consensus guidelines. BMC Neurol 2020;20:44. [PMID: 32013931 DOI: 10.1186/s12883-020-1605-y] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
20 Vitiello G, Emmi G, Silvestri E, Di Scala G, Palterer B, Parronchi P. Intravenous immunoglobulin therapy: a snapshot for the internist. Intern Emerg Med 2019;14:1041-9. [PMID: 31309519 DOI: 10.1007/s11739-019-02150-z] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
21 Abbas A, Rajabally YA. Complications of Immunoglobulin Therapy and Implications for Treatment of Inflammatory Neuropathy: A Review. Curr Drug Saf 2019;14:3-13. [PMID: 30332974 DOI: 10.2174/1574886313666181017121139] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 1.5] [Reference Citation Analysis]
22 Jayakumar D, Zhang R, Wasserman A, Ash J. Cardiac Manifestations in Idiopathic Inflammatory Myopathies: An Overview. Cardiology in Review 2019;27:131-7. [DOI: 10.1097/crd.0000000000000241] [Cited by in Crossref: 12] [Cited by in F6Publishing: 16] [Article Influence: 3.0] [Reference Citation Analysis]
23 Huijbers MG, Plomp JJ, van Es IE, Fillié-Grijpma YE, Kamar-Al Majidi S, Ulrichts P, de Haard H, Hofman E, van der Maarel SM, Verschuuren JJ. Efgartigimod improves muscle weakness in a mouse model for muscle-specific kinase myasthenia gravis. Exp Neurol 2019;317:133-43. [PMID: 30851266 DOI: 10.1016/j.expneurol.2019.03.001] [Cited by in Crossref: 14] [Cited by in F6Publishing: 15] [Article Influence: 3.5] [Reference Citation Analysis]
24 Rungjirajittranon T, Owattanapanich W. A serious thrombotic event in a patient with immune thrombocytopenia requiring intravenous immunoglobulin: a case report. J Med Case Rep 2019;13:25. [PMID: 30686269 DOI: 10.1186/s13256-018-1955-x] [Cited by in Crossref: 8] [Cited by in F6Publishing: 10] [Article Influence: 2.0] [Reference Citation Analysis]
25 Zhang X, Owens J, Olsen HS, So E, Burch E, McCroskey MC, Li X, Weber GL, Bennett D, Rybin D, Zhou H, Hao H, Mérigeon EY, Block DS, LaRosa G, Strome SE. A recombinant human IgG1 Fc multimer designed to mimic the active fraction of IVIG in autoimmunity. JCI Insight 2019;4:121905. [PMID: 30674715 DOI: 10.1172/jci.insight.121905] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 3.8] [Reference Citation Analysis]
26 Kornilova OG, Krivykh MA, Kudasheva ÉY, Borisevich IV. Technological Aspects of Ensuring the Specific Safety of Human Immunoglobulin and Albumin Preparations. Pharm Chem J 2018;52:473-477. [DOI: 10.1007/s11094-018-1842-1] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
27 Sala TP, Crave JC, Duracinsky M, Lepira Bompeka F, Tadmouri A, Chassany O, Cherin P. Efficacy and patient satisfaction in the use of subcutaneous immunoglobulin immunotherapy for the treatment of auto-immune neuromuscular diseases. Autoimmun Rev 2018;17:873-81. [PMID: 30005853 DOI: 10.1016/j.autrev.2018.03.010] [Cited by in Crossref: 13] [Cited by in F6Publishing: 15] [Article Influence: 2.6] [Reference Citation Analysis]
28 Loan HT, Yen LM, Kestelyn E, Hao NV, Mai NTH, Thuy DB, Duong HTH, Dung NTP, Phu NH, Lieu PT, Thanh TT, Geskus R, van Doorn HR, Tan LV, Wyncoll D, Day NPJ, Hien TT, Thwaites GE, Chau NVV, Thwaites CL. A Pilot Study to Assess Safety and Feasibility of Intrathecal Immunoglobulin for the Treatment of Adults with Tetanus. Am J Trop Med Hyg 2018;99:323-6. [PMID: 29916342 DOI: 10.4269/ajtmh.18-0153] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
29 Burnouf T. What can be learned in the snake antivenom field from the developments in human plasma derived products? Toxicon 2018;146:77-86. [PMID: 29621528 DOI: 10.1016/j.toxicon.2018.04.002] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
30 Algaze SD, Park W, Harrington TJ, Mudad R. Autoimmune haemolytic anaemia in a patient with advanced lung adenocarcinoma and chronic lymphocytic leukaemia receiving nivolumab and intravenous immunoglobulin. BMJ Case Rep 2018;2018:bcr-2017-221801. [PMID: 29523604 DOI: 10.1136/bcr-2017-221801] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
31 Vassilev TL, Kostov V, von Gunten S, Pashov AD. Basics of Immunoglobulins as Effector Molecules and Drugs. Antibody Therapy 2018. [DOI: 10.1007/978-3-319-68038-5_11] [Reference Citation Analysis]
32 Wahn V, Späth P. Historical Aspects of Polyclonal IgG Preparations. Antibody Therapy 2018. [DOI: 10.1007/978-3-319-68038-5_10] [Reference Citation Analysis]
33 Späth PJ. Essentials of the Production of Safe and Efficacious State-of-the-Art Polyclonal IgG Concentrates. Antibody Therapy 2018. [DOI: 10.1007/978-3-319-68038-5_12] [Reference Citation Analysis]
34 Späth PJ. Current IgG Products and Future Perspectives. Antibody Therapy 2018. [DOI: 10.1007/978-3-319-68038-5_13] [Reference Citation Analysis]
35 Goudouris ES, Rego Silva AM, Ouricuri AL, Grumach AS, Condino-Neto A, Costa-Carvalho BT, Prando CC, Kokron CM, Vasconcelos DM, Tavares FS, Silva Segundo GR, Barreto IC, Dorna MB, Barros MA, Forte WCN. II Brazilian Consensus on the use of human immunoglobulin in patients with primary immunodeficiencies. Einstein (Sao Paulo) 2017;15:1-16. [PMID: 28444082 DOI: 10.1590/S1679-45082017AE3844] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 1.5] [Reference Citation Analysis]
36 Gurevich-Shapiro A, Bonstein L, Spectre G, Atweh N, Gruenewal T, Shapiro M, Tadmor B, Raanani P. Intravenous immunoglobulin-induced acute thrombocytopenia. Transfusion 2018;58:493-7. [PMID: 29193103 DOI: 10.1111/trf.14419] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
37 Cicha A, Fischer MB, Wesinger A, Haas S, Bauer WM, Wolf HM, Sauerwein KMT, Reininger B, Petzelbauer P, Pehamberger H, Handisurya A. Effect of intravenous immunoglobulin administration on erythrocyte and leucocyte parameters. J Eur Acad Dermatol Venereol 2018;32:1004-10. [PMID: 29114967 DOI: 10.1111/jdv.14671] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 1.3] [Reference Citation Analysis]
38 Mielke O, Fontana S, Goranova-Marinova V, Shebl A, Spycher MO, Wymann S, Durn BL, Lawo JP, Hubsch A, Salama A. Hemolysis related to intravenous immunoglobulins is dependent on the presence of anti-blood group A and B antibodies and individual susceptibility. Transfusion 2017;57:2629-38. [PMID: 28840942 DOI: 10.1111/trf.14289] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 2.7] [Reference Citation Analysis]
39 Corbí AL, Sánchez-Ramón S, Domínguez-Soto A. The potential of intravenous immunoglobulins for cancer therapy: a road that is worth taking? Immunotherapy 2016;8:601-12. [PMID: 27140412 DOI: 10.2217/imt.16.9] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 1.3] [Reference Citation Analysis]
40 Gerber S, Gaida A, Spiegl N, Wymann S, Antunes AM, Menyawi IE, Zurbriggen B, Hubsch A, Imboden M. Reduction of Isoagglutinin in Intravenous Immunoglobulin (IVIG) Using Blood Group A- and B-Specific Immunoaffinity Chromatography: Industry-Scale Assessment. BioDrugs 2016;30:441-51. [PMID: 27646589 DOI: 10.1007/s40259-016-0192-3] [Cited by in Crossref: 19] [Cited by in F6Publishing: 17] [Article Influence: 3.2] [Reference Citation Analysis]
41 Kowalski ML, Ansotegui I, Aberer W, Al-Ahmad M, Akdis M, Ballmer-Weber BK, Beyer K, Blanca M, Brown S, Bunnag C. Risk and safety requirements for diagnostic and therapeutic procedures in allergology: World Allergy Organization Statement. World Allergy Organ J. 2016;9:33. [PMID: 27777642 DOI: 10.1186/s40413-016-0122-3] [Cited by in Crossref: 61] [Cited by in F6Publishing: 66] [Article Influence: 8.7] [Reference Citation Analysis]
42 Späth PJ, Schneider C, von Gunten S. Clinical Use and Therapeutic Potential of IVIG/SCIG, Plasma-Derived IgA or IgM, and Other Alternative Immunoglobulin Preparations. Arch Immunol Ther Exp 2017;65:215-31. [DOI: 10.1007/s00005-016-0422-x] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 2.0] [Reference Citation Analysis]
43 Pinte L, Vergez J, Liou A, Leger J, Thibault V. Interprétation des tests sérologiques : ne pas oublier le transfert passif des immunoglobulines ! La Presse Médicale 2016;45:676-81. [DOI: 10.1016/j.lpm.2016.03.009] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
44 Pulvirenti F, Granata G, Girelli G, Quinti I. Immunoglobulin-induced hemolysis, splenomegaly and inflammation in patients with antibody deficiencies. Expert Rev Clin Immunol 2016;12:725-31. [PMID: 26854522 DOI: 10.1586/1744666X.2016.1151787] [Reference Citation Analysis]
45 Struble EB, Kirschbaum N, Liu J, Marszal E, Shapiro M. Characterization of Therapeutic Proteins. Topics in Medicinal Chemistry 2016. [DOI: 10.1007/7355_2015_5005] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
46 Jovanovich E, Karam C. Human immune globulin infusion in the management of multifocal motor neuropathy. Degener Neurol Neuromuscul Dis 2016;6:1-12. [PMID: 30050363 DOI: 10.2147/DNND.S96258] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
47 Cherin P, Marie I, Michallet M, Pelus E, Dantal J, Crave JC, Delain JC, Viallard JF. Management of adverse events in the treatment of patients with immunoglobulin therapy: A review of evidence. Autoimmun Rev 2016;15:71-81. [PMID: 26384525 DOI: 10.1016/j.autrev.2015.09.002] [Cited by in Crossref: 75] [Cited by in F6Publishing: 83] [Article Influence: 9.4] [Reference Citation Analysis]
48 Farrugia A, Visentini M, Quinti I. Editorial: Immunoglobulin Therapy in the 21st Century - the Dark Side of the Moon. Front Immunol 2015;6:436. [PMID: 26379671 DOI: 10.3389/fimmu.2015.00436] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
49 Yu CF, Hou JF, Shen LZ, Gao K, Rao CM, Yang PY, Fu ZH, Wang QZ, Li YH, Wang L, Liu F, Zhang L, Qu Z, Shen Q, Li B, Li XG, Wang JZ. Acute pulmonary embolism caused by highly aggregated intravenous immunoglobulin. Vox Sang 2016;110:27-35. [PMID: 26198276 DOI: 10.1111/vox.12307] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.5] [Reference Citation Analysis]
50 Hoffman TW, van Kessel DA, van Velzen-blad H, Grutters JC, Rijkers GT. Antibody replacement therapy in primary antibody deficiencies and iatrogenic hypogammaglobulinemia. Expert Review of Clinical Immunology 2015;11:921-33. [DOI: 10.1586/1744666x.2015.1049599] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.6] [Reference Citation Analysis]